Sufentanil Pharmacokinetics After Intra Amniotic Injection

Assessment of Fetal and Maternal Sufentanil Pharmacokinetics After Intra-amniotic Injection

The fetus may be exposed during pregnancy to nociceptive stimuli because of fetal pathology (e.g., malformation) or a diagnostic or therapeutic procedure.

To date, there is very little data and no consensus on fetal analgesia. The aim of the investigators study is to evaluate the pharmacokinetics of Sufentanil after intra amniotic injection.

Inclusion Criteria:

• Termination of pregnancy for fetal malformation
• Gestational age > 24 weeks of gestation

Exclusion Criteria:

• Multiple pregnancy
• Allergy or contraindication to sufentanil
• Morphinic addiction
• fetal gastroschisis, omphalocele or swallowing disorder
• maternal cardiac or respiratory distress